Antibodies Screening in Multiple Sclerosis as a Part of an International Survey in Autoimmune Diseases.
Overview
- Phase
- Phase 1
- Intervention
- Not specified
- Conditions
- Multiple Sclerosis
- Sponsor
- Sheba Medical Center
- Enrollment
- 100
- Locations
- 1
- Primary Endpoint
- Determine antibodies to infectious agents immunoglobulin G (IgG), IgM in patients with multiple sclerosis
- Last Updated
- 20 years ago
Overview
Brief Summary
The purpose of this investigation is to assess the prevalence of infectious disease seropositivity (toxoplasmosis, rubella, cytomegalovirus [CMV]), herpes simplex virus type 1 (HSV-1) and herpes simplex virus type 2 (HSV-2), syphilis, Epstein-Barr virus and H. pylori in a group of patients presenting with specific autoimmune diseases (rheumatoid arthritis [RA], undifferentiated connective tissue disorder [UCTD], Sjogren, antiphospholipid syndrome - APS, vasculitides, systemic lupus erythematosus [SLE], polymyositis, Hashimoto, multiple sclerosis, primary biliary cirrhosis [PBC], etc.), using the BioPlex 2200 and complementary EIA kits as compared to matched controls (by age, sex and ethnicity).
Detailed Description
The purpose of this investigation is to assess the prevalence of infectious disease seropositivity (toxoplasmosis, rubella, cytomegalovirus \[CMV\]), herpes simplex virus type 1 (HSV-1) and herpes simplex virus type 2 (HSV-2), syphilis, Epstein-Barr virus and H. pylori in a group of patients presenting with specific autoimmune diseases (RA, UCTD, Sjogren, antiphospholipid syndrome - APS, vasculitides, SLE, polymyositis, Hashimoto, multiple sclerosis, PBC, etc.), using the BioPlex 2200 and complementary EIA kits as compared to matched controls (by age, sex and ethnicity). We will assess in our Center 100 patients with multiple sclerosis for the antibody profile of different infectious agents. Comparative assessments will be performed with normal matched subjects.
Investigators
Eligibility Criteria
Inclusion Criteria
- •Definite multiple sclerosis
Exclusion Criteria
- •Intravenous immune globulin (IVIg) treatment
Outcomes
Primary Outcomes
Determine antibodies to infectious agents immunoglobulin G (IgG), IgM in patients with multiple sclerosis
Secondary Outcomes
- Assess correlation between antibody levels to various infectious agents with clinical disease variables